Daniel M. Lerman

Is Prophylactic Intervention More Cost-effective Than the Treatment of Pathologic Fractures in Metastatic Bone Disease?

Alan T. Blank, Daniel M. Lerman, Neeraj M. Patel et al. · Clinical Orthopaedics and Related Research · 2016 · 73 citations · Full text

Tumoral <i>TP53</i> and/or <i>CDKN2A</i> alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: A report from the Children's Oncology Group

Daniel M. Lerman, Michael J. Monument, Elizabeth McIlvaine et al. · Pediatric Blood & Cancer · 2014 · 51 citations

Use of Compressive Osseointegration Endoprostheses for Massive Bone Loss From Tumor and Failed Arthroplasty: A Viable Option in the Upper Extremity

Krista Goulding, Adam J. Schwartz, Steven J. Hattrup et al. · Clinical Orthopaedics and Related Research · 2017 · 28 citations · Full text

Identification of a Novel Membrane-Associated Gene Product That Suppresses Toxicity of a TrfA Peptide from Plasmid RK2 and Its Relationship to the DnaA Host Initiation Protein

Peter D. Kim, Trevor Banack, Daniel M. Lerman et al. · Journal of Bacteriology · 2003 · 22 citations · Full text

Molecular Biology, Escherichia Coli, Protein Synthesis +18

PROMIS^® scores in operative metastatic bone disease patients: A multicenter, prospective study

Alan T. Blank, Daniel M. Lerman, Sara Shaw et al. · Journal of Surgical Oncology · 2018 · 22 citations